Focus Partners Advisor Solutions’s Iovance Biotherapeutics IOVA Stock Holding History

Focus Partners Advisor Solutions’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$198K	Buy	+13,384	New	+$95.8K	﹤0.01%	1302

Other funds holding IOVA

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Jupiter Asset Management London, United Kingdom $21.4B AUM 19.74% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Orion Investment Company St. Louis, Missouri $377M AUM 66.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

C WorldWide Group Copenhagen, Denmark $3.96B AUM 10.41% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return

Focus Partners Advisor Solutions's IOVA Position: Q3 2026 in Review

Focus Partners Advisor Solutions opened a new position in Iovance Biotherapeutics (IOVA) in Q3 2026: 13,384 shares worth $198K. The stake represents ﹤0.01% of the portfolio and ranks #1302 among its holdings.

162 funds tracked by Wall St. Rank hold IOVA as of Q3 2026.

Focus Partners Advisor Solutions held 13,384 shares of Iovance Biotherapeutics worth $198K as of Q3 2026.
Iovance Biotherapeutics was a new Focus Partners Advisor Solutions position in Q3 2026.
Iovance Biotherapeutics made up ﹤0.01% of Focus Partners Advisor Solutions's portfolio in Q3 2026, its #1302 holding.
162 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2026.

Based on Focus Partners Advisor Solutions's 13F filing for Q3 2026, filed 10 Nov 2026.